RxDoctor Payments Data

Michael Sumsion, MD

Ophthalmology · Redding, CANPI 1699725507

Payments from drug & device makers

$4,106in general payments, 2019–2025

Across 183 payments — averaging $22.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$674
  • Bausch & Lomb Americas Inc.$533
  • Biotissue Holdings Inc.$399
  • Regeneron Healthcare Solutions, Inc.$365
  • Mallinckrodt Hospital Products Inc.$296
  • Apellis Pharmaceuticals, Inc.$265
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$4,04999%
  • Education$180%
  • Gifts$391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,106 in reported general payments places this provider in the 70th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$4,803,003
Medicare patients
2,058
Services billed
28,672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost196$101,715
CombiganBrimonidine Tartrate/Timolol50$19,806
XiidraLifitegrast20$18,672
MieboPerfluorohexyloctane/Pf20$14,433
VyzultaLatanoprostene Bunod35$12,395
Alphagan PBrimonidine Tartrate38$12,283
RestasisCyclosporine12$10,940
Cyclosporine18$8,279
RocklatanNetarsudil Mesylat/Latanoprost19$7,831
Prednisolone Acetate141$5,961
Brimonidine Tartrate37$5,306
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol35$3,984
Travoprost34$3,479
SimbrinzaBrinzolamide/Brimonidine Tart14$2,778
Timolol Maleate218$1,983

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P, Restasis$674$144,744296 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$533$45,50075 claims
AlconSimbrinza$206$2,77814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Redding

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →